INTERIM RESULTS AS OF SEPTEMBER 30, 2016

Q3

CSE/OMX:BAVA, OTC:BVNRY

BAVARIAN NORDIC

FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements regarding our short-term objectives and opportunities, financial expectations for the full year and financial preparedness as of year end, as well as statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

HIGHLIGHTS
FOR THE THIRD QUARTER 2016 AND UP TO DATE

- Phase 1 results for the MVA-BN RSV vaccine were presented at the 10th International Respiratory Syncytial Virus Symposium
- Phase 2 trial of MVA-BN RSV initiated to help identify optimal dose and schedule for a subsequent Phase 2b field efficacy study planned for 2017
- Phase 2 combination trial of PROSTVAC and ipilimumab in patients with localized prostate cancer initiated and sponsored at UCSF
- Interim analysis #2 of PROSTVAC Phase 3 (at 60% or 321 events) confirmed that the study continues without modification
- Christopher Heery, M.D. appointed Chief Medical Officer. He will be located in a new office to be established on the U.S. east coast
- Janssen completed a submission for Emergency Use Assessment and Listing for the Ebola vaccine regimen to the World Health Organization

SUCCESSFUL EXPANSION OF PIPELINE

Initiated & planned studies Q3 and Q4 2016

Initiated

MVA-BN RSV Phase 2

- Dose ranging, 400 subjects, immunological endpoints

PROSTVAC + ipilimumab Phase 2 combo

Bristol-Myers Squibb

- 75 pts with localized prostate cancer (USCF)

Planned

CV301 + nivolumab proof of concept study

Bristol-Myers Squibb

- ~160 pts with NSCLC
- Phase 1 safety study component shortly followed by randomized Phase 2

PROSTVAC + ipilimumab and/or nivolumab Phase 2 combo

Bristol-Myers Squibb

- 65 pts with localized prostate cancer (NCI)

CV301 CANCER IMMUNOTHERAPY
DESIGNED FOR THE TREATMENT OF MULTIPLE CANCERS

Developing CV301 in combination with checkpoint inhibitors

- Proof-of-concept studies of CV301 plus PD-1/PD-L1 being explored in company collaborations or with NCI
- NSCLC targeted as first indication in BN sponsored trial
- Additional indications under evaluation

New and improved construct leverages existing clinical data

- Preliminary evidence of efficacy generated in multiple clinical studies
- Safety data with over 300 subjects treated

MVA-BN RSV
RESPIRATORY SYNCYTIAL VIRUS VACCINE CANDIDATE

Large unmet medical need: children & elderly

- Global RSV disease burden is estimated at 64 million cases and 160,000 deaths every year
- The U.S. Centers for Disease Control and Prevention (CDC) reports that each year the disease causes 177,000 hospitalizations and 14,000 deaths among adults older than 65
- No approved prophylactic vaccine available
- Recent failures highlight need for differentiated approach

MVA-BN RSV vaccine candidate

- Protection against both RSV subtypes (A&B) in preclinical models
- Blood and mucosal protection (*key differentiator*)
- 400 pts Phase 2 ongoing with data read out mid-2017



PROSTVAC: INTERIM ANALYSES UNDERWAY

Second interim analysis of the PROSPECT Phase 3 study has occurred

- A recent review by the Data Monitoring Committee informed BN to "Continue the trial without modification"
- Interim 2 was an analysis of each of the active PROSTVAC arms (with or without GM-CSF) versus placebo, thus requiring at least 321 events per comparison (equals 60% of the 534 events required for final overall survival analysis)
- 1 additional interim analysis remain
- Final overall survival data anticipated in 2017

Interim Analysis #1	✓	214 events	40%
Interim Analysis #2	✓	321 events	60%
Interim Analysis #3		427 events	80%
Final Overall Survival Analysis		534 events	100%

PROSPECT ENROLLMENT BY QUARTERS



PIPELINE

PRODUCT	INDICATION	ONGOING STUDIES	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKET	COMMERCIAL RIGHTS
INFECTIOUS DISEASES								
IMVAMUNE liquid-frozen [1)]	*Smallpox*	1						Bavarian Nordic
IMVAMUNE freeze-dried	*Smallpox*	-						Bavarian Nordic
MVA-BN Filo	*Ebola/Marburg*	10						Janssen
MVA-BN RSV	*RSV*	1						Bavarian Nordic
MVA-BN HPV	*Chronic HPV Infection*	-						Janssen
CANCER IMMUNOTHERAPY								
PROSTVAC	*Prostate Cancer*	10						Bristol-Myers Squibb
CV301	*Lung Cancer (NSCLC)*	1						Bavarian Nordic
MVA-BN Brachyury	*Metastatic Tumors*	1						Bavarian Nordic

1) Approved in the European Union under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Phase 3 registration studies are ongoing in the United States.

ANTICIPATED SELECTED MILESTONES
2016/2017

IMVAMUNE
- U.S. RFP for freeze-dried IMVAMUNE

RSV
- MVA-BN RSV Phase 2 dosing study read out
- MVA-BN RSV Phase 2 field efficacy initiation

Janssen
- Initiate HPV Phase 1 study in cervical cancer
- Potential expanded collaboration with Janssen on two additional infectious disease targets
- Data from Phase 2 and Phase 3 studies of the Ebola prime-boost vaccine regimen

PROSTVAC
- Phase 3 top-line data including interim analyses
- Data from NCI-sponsored Phase 2 trials
- Initiate NCI-sponsored Phase 2 study in combination with ipilimumab and nivolumab

CV301
- CV301 + nivolumab proof-of-concept study initiation in lung cancer
- CV301 + checkpoint inhibitor proof-of-concept studies in additional indications

Brachyury
- MVA-BN Brachyury Phase 2 initiation

FINANCIALS

Q3 revenues as expected

- Remaining 40% of this year's revenue will be recognized in Q4 2016
- FY revenue and EBIT expectations maintained

	DKK million			USD million		
	9m 2016	9m 2015	**FY2016E**	**9m 2016**	9m 2015	**FY2016E**
Revenue	591	703	1,000	88	105	150
EBIT	(82)	2	0	(12)	0	0
Cash preparedness	1,647	1,618	1,900	247	242	284

Main assumptions for FY2016E: Revenue of DKK 750 million from IMVAMUNE sales and DKK 250 million from R&D contracts. Total R&D costs of DKK 580 million, which include DKK 110 million in contract expenses (stated under production costs in the P&L statement) as well as DKK 25 million capitalized in the balance sheet. Cash preparedness includes cash, cash equivalents, investments in securities and the aggregate amount of undrawn credit lines.
USD/DKK = 6.68 (as of September 30, 2016)
All numbers are approximate.

FINANCIAL STATEMENTS

DKK million	9m 2016	9m 2015	FY 2015
Revenue	591	703	1,021
Production costs	192	246	415
Gross profit	**399**	**457**	**605**
Research and development costs	324	297	387
Distribution and administrative costs	157	158	217
Total operating costs	**481**	**455**	**604**
Income before interest and taxes (EBIT)	**(82)**	**2**	**2**
Financial income/loss	3	58	76
Income before company tax	**(78)**	**60**	**78**
Tax	(22)	3	18
Net profit for the period	**(57)**	**57**	**59**
Cash preparedness (end of period)	**1,647**	**1,648**	**1,451**

Q&A